Pancreatic Enteroendocrine Cells are specialized cells scattered throughout the pancreas, primarily in the islets of Langerhans, and are responsible for producing hormones that play crucial roles in glucose homeostasis and digestive processes. While the majority of the pancreas consists of exocrine tissue involved in enzyme secretion for digestion, the endocrine component, comprising enteroendocrine cells, is vital for regulating hormonal balance. The enteroendocrine cells in the pancreas secrete hormones such as glucagon, insulin, somatostatin, and pancreatic polypeptide. These hormones collectively contribute to the regulation of blood glucose levels, pancreatic and gastric secretion, and various metabolic processes. Beta cells within the islets of Langerhans are a subset of enteroendocrine cells that produce insulin, a hormone essential for glucose uptake by cells. Alpha cells secrete glucagon, which elevates blood glucose levels by promoting the release of stored glucose from the liver. Delta cells produce somatostatin, inhibiting the release of insulin and glucagon and modulating digestive functions. Disturbances in the function of pancreatic enteroendocrine cells can lead to metabolic disorders, such as diabetes mellitus. In type 1 diabetes, autoimmune destruction of beta cells impairs insulin production, while in type 2 diabetes, beta cells may become less responsive to insulin. Research into pancreatic enteroendocrine cells is critical for understanding the intricate regulation of glucose metabolism and developing targeted therapies for diabetes. Efforts to promote the survival and function of beta cells, as well as exploring the potential of transdifferentiation to convert other cell types into insulin-producing cells, represent avenues for advancing diabetes treatments. In summary, pancreatic enteroendocrine cells play a pivotal role in hormonal regulation, impacting glucose metabolism and digestive processes. Understanding their functions and dysregulations is essential for addressing metabolic disorders and developing effective treatments for conditions like diabetes.
Title : AI-integrated high-throughput tissue-chip for space-based biomanufacturing applications
Kunal Mitra, Florida Tech, United States
Title : Stem cell technologies to integrate biodesign related tissue engineering within the frame of cell based regenerative medicine: towards the preventive therapeutic and rehabilitative resources and benefits
Sergey Suchkov, N.D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences, Russian Federation
Title : In vitro evaluation of lyophilized Dedifferentiated Fat cells (DFAT) impregnated artificial dermis
Kazutaka Soejima, Nihon University, School of Medicine, Japan
Title :
Nagy Habib, Imperial College London, United Kingdom
Title :
Alexander Seifalian, Nanotechnology & Regenerative Medicine Commercialisation Centre, United Kingdom
Title : The regenerative medicine of the future
Marco Polettini, DVM, Italy